Chasing Graphene-Based Anticancer Drugs: Where are We Now on the Biomedical Graphene Roadmap?
Katarzyna Uzdrowska,Narcyz Knap,Jacek Gulczynski,Alicja Kuban-Jankowska,Wiktoria Struck-Lewicka,Michal Markuszewski,Tomasz Bączek,Ewa Izycka-Swieszewska,Magdalena Gorska-Ponikowska
DOI: https://doi.org/10.2147/ijn.s447397
IF: 7.033
2024-05-03
International Journal of Nanomedicine
Abstract:Katarzyna Uzdrowska, 1 Narcyz Knap, 1 Jacek Gulczynski, 2 Alicja Kuban-Jankowska, 1 Wiktoria Struck-Lewicka, 3 Michal J Markuszewski, 3 Tomasz B&aogonczek, 3 Ewa Izycka-Swieszewska, 2 Magdalena Gorska-Ponikowska 1 1 Department of Medical Chemistry, Medical University of Gdansk, Gdansk, 80-211, Poland; 2 Faculty of Health Sciences with the Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Gdansk, 80-211, Poland; 3 Faculty of Pharmacy, Medical University of Gdansk, Gdansk, 80-416, Poland Correspondence: Magdalena Gorska-Ponikowska, Department of Medical Chemistry, Medical University of Gdansk, 1 Debinki St, Gdansk, 80-211, Poland, Tel +48 58 349 14 50, Fax +48 58 349 14 56, Email Graphene and graphene-based materials have attracted growing interest for potential applications in medicine because of their good biocompatibility, cargo capability and possible surface functionalizations. In parallel, prototypic graphene-based devices have been developed to diagnose, imaging and track tumor growth in cancer patients. There is a growing number of reports on the use of graphene and its functionalized derivatives in the design of innovative drugs delivery systems, photothermal and photodynamic cancer therapy, and as a platform to combine multiple therapies. The aim of this review is to introduce the latest scientific achievements in the field of innovative composite graphene materials as potentially applied in cancer therapy. The "Technology and Innovation Roadmap" published in the Graphene Flagship indicates, that the first anti-cancer drugs using graphene and graphene-derived materials will have appeared on the market by 2030. However, it is necessary to broaden understanding of graphene-based material interactions with cellular metabolism and signaling at the functional level, as well as toxicity. The main aspects of further research should elucidate how treatment methods (e.g., photothermal therapy, photodynamic therapy, combination therapy) and the physicochemical properties of graphene materials influence their ability to modulate autophagy and kill cancer cells. Interestingly, recent scientific reports also prove that graphene nanocomposites modulate cancer cell death by inducing precise autophagy dysfunctions caused by lysosome damage. It turns out as well that developing photothermal oncological treatments, it should be taken into account that near-infrared-II radiation (1000– 1500 nm) is a better option than NIR-I (750– 1000 nm) because it can penetrate deeper into tissues due to less scattering at longer wavelengths radiation. Keywords: graphene-based materials, oncological therapies, cancer treatment, biomedical innovations, drugs delivery systems Chemotherapy is currently one of the main methods of cancer treatment, but its effectiveness is limited due to systemic toxicity, suboptimal effectiveness and chemoresistance of cancer cells. For this reason, more selective therapeutic methods development is needed. These modern methods among others are based mainly on the use of materials that can act as carriers of anti-cancer drugs with unique biophysicochemical properties, especially in the area of binding xenobiotics and physiological metabolites, including absorption and penetration of biological membranes, volume of distribution, and therefore bioavailability and potential selectivity of the chemotherapeutic agent. 1–4 One of these types of materials that has recently been widely researched for use in oncological therapies is graphene. This material was invented in 2004, but the real race of scientists to use it commercially in various fields of science began a few years later, when it began to be produced in large quantities. Graphene (GN) is an allotropic form of carbon and, as a single graphite layer, it has recently been one of the most intensely investigated two-dimensional (2DM) materials. Graphene structure is based on a densely packed hexagonal crystal lattice one-atom thick. Carbon atoms are all sp 2 hybridized forming six-membered rings arranged in a kind of honeycomb lattice. The honeycomb structure of graphene having a thickness of one atom consists of soft equivalent subnets connected by σ bonds, each carbon atom having a relatively labile pair of π electrons contributing to a delocalized electron lattice. The labile π electrons are responsible for relatively higher electron density right below and above the 2D plane of the graphene monolayer. These electrons, by means of easy interaction with the boundary molecular orbitals of different organic compounds, to a large extent facilitate electrophilic substitution reactions as opposed to nucleophilic substitution ones. The planar structure of graphene also enables partici -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology